Sign Up

About ARALAST NP Therapy

ARALAST NP ARALAST NP

Professional Kits and Brochures

AATD Physician Kit

ARALAST Patient Education Kit

The AATD Physician Kit is a helpful resource for physicians managing an AATD patient. In addition to the AATD physician brochure, there are materials to help you and your patient get started with ARALAST NP therapy and with the ARALAST NP AATmosphere program.

Baxter is pleased to provide you with this kit, which includes:

  • Take a Closer Look Booklet—information for physicians on testing for AATD, therapy, and patient benefits
  • ARALAST NP AATmosphere Program Overview—program and enrollment materials for your patients
  • ARALAST NP AATmosphere Program Enrollment Forms—referral and enrollment in one simple form
  • ARALAST NP Materials Form—Order additional materials for you and your patients
Order AATD Physician Kit

You may order an AATD Physician Kit online or by phone at 1-866-ARALAST (272-5278).

AATD Physician Booklet

ARALAST Patient Education Kit

Take a closer look at alpha1-antitrypsin deficiency (AATD) with this updated booklet from Baxter.

Find information about:

  • Prevalence and characteristics of AATD
  • ATS/ERS standards for testing
  • Using AlphaTest® Kits
  • ARALAST NP Therapy
  • Patient Support Services from ARALAST NP AATmosphere Program
Order AATD Physician Brochure

You may order the Physician Booklet online or by phone at 1-866-ARALAST (272-5278).

You may also download a copy of the booklet.

ARALAST NP [Alpha1-Proteinase Inhibitor (Human)]

ARALAST NP is indicated for chronic augmentation therapy in patients having congenital deficiency of A1-PI with clinically evident emphysema. ARALAST NP is not indicated as therapy for lung disease patients in whom congenital A1-PI deficiency has not been established.

The effect of augmentation therapy with ARALAST NP on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials.

Please review the Important Risk Information and the Full Prescribing Information

Please review the Important Risk Information and the Full Prescribing Information